Urtica dioica for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Urtica dioica may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed Urtica dioica in detail.

Studies suggesting benefit with Urtica dioica

Akbas et al., Integrated Evaluation of Urtica dioica Extract Assessing Physiochemical Analysis with Antioxidant, Antiviral, and Immunomodulatory Effects Against SARS-CoV-2, Pharmaceuticals, doi:10.3390/ph19050693

Background: A major challenge in antiviral development is the identification of novel virus–host interactions while ensuring therapeutic efficacy and safety. These challenges have renewed interest in phytochemicals derived from medicinal plants as alternative antiviral agents. Objectives: In this study, we investigated the antioxidant, antiviral, and immunomodulatory properties of a Mediterranean Urtica dioica extract (UdE) against SARS-CoV-2 using chemical, biochemical, and in vitro approaches. Methods: The physicochemical properties of UdE were characterized using microtiter assays and HPLC analysis. Cytocompatibility was evaluated in HEK293T, Vero E6, Caco-2, and Calu-3 cell lines while antioxidant activity was assessed using both chemical and cell-based assays. Antiviral activity was evaluated by assessing inhibition of SARS-CoV-2 receptor binding domain (RBD)–ACE2 interaction using ELISA, inhibition of SARS-CoV-2 main protease (Mpro) activity via FRET assay and inhibition of viral entry using SARS-CoV-2 S1 pseudovirus neutralization assay. Results: UdE (100 µg/mL) inhibited RBD–ACE2 binding by 94% and suppressed Mpro activity by 74%, while reducing moderate but significant inhibition of pseudovirus entry (33.6%) at 300 µg/mL dose level in ACE2 expressing HEK293T cells. Immunomodulatory analysis revealed significant suppression of IL-1β and IL-6 production, accompanied by increased TNF-α and IL-8 levels. Conclusions: Collectively, these findings highlight that UdE exhibits multi-target in vitro antioxidant, antiviral, and immunomodulatory activity against SARS-CoV-2; therefore, UdE represents a promising bioactive extract for the management of SARS-CoV-2 infection.

Cherneva et al., Traditional Use of Medicinal Plants for Symptom Relief During the COVID-19 Pandemic in Bulgaria, Plants, doi:10.3390/plants14233692

The COVID-19 pandemic has renewed global interest in medicinal plants as accessible sources of prophylactic and supportive therapies. Ethnobotanical research provides an important foundation for developing plant-based medicines with preventive and therapeutic potential. This study aimed (1) to investigate the distribution and indications for the use of medicinal plants in the prevention and relief of COVID-19-related symptoms among the Bulgarian population, and (2) to identify culturally significant species with potential for further development as antiviral agents. A total of 513 respondents from different regions and demographic groups in Bulgaria were interviewed. Their knowledge regarding the use of medicinal plants for COVID-19 prevention or treatment was quantitatively assessed using ethnobotanical indices: relative frequency of citation (RFC), informant consensus factor (FIC), fidelity level (FL), and use value (UV). Participants reported 45 species belonging to 43 genera and 23 families. The highest RFC and UVs were recorded for Matricaria chamomilla L., Tilia sp., Thymus vulgaris L., Zingiber officinale Roscoe, Mentha sp., Citrus x limon (L.) Osbeck, Rosa canina L., and Sideritis scardica Griseb. Culturally significant species identified were Thymus vulgaris L., Matricaria chamomilla L., Tilia sp., Mentha sp., Sideritis scardica Griseb, Zingiber officinale Roscoe, and Citrus x limon (L.) Osbeck. This ethnobotanical survey in Bulgaria documents culturally important medicinal plants that may have potential applications in prophylaxis and complementary therapy for COVID-19.